RETRACTED: Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis

Transl Res. 2022 Jan:239:35-43. doi: 10.1016/j.trsl.2021.04.010. Epub 2021 May 7.

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the authors after consulting with the Editors. During a follow-up study, the authors regretfully discovered that the microarray probe-to-gene mapping was incorrect. Although the methodology and primary findings remain the same, the identity of the biomarker genes are incorrect as a result of this honest mistake. The extent of the changes to correct this information necessitated the publication of a corrected version of this article: https://doi.org/10.1016/j.trsl.2022.03.006.

Publication types

  • Retracted Publication

MeSH terms

  • Area Under Curve
  • Biomarkers
  • Case-Control Studies
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / genetics*
  • Colitis, Ulcerative / metabolism
  • Gastrointestinal Agents / therapeutic use
  • Gene Expression / drug effects*
  • Humans
  • Infliximab / therapeutic use*
  • Intestinal Mucosa / drug effects
  • Protein Interaction Maps / genetics
  • Reproducibility of Results
  • Treatment Outcome

Substances

  • Biomarkers
  • Gastrointestinal Agents
  • Infliximab